S
Scott M. Wasserman
Researcher at Amgen
Publications - 127
Citations - 17995
Scott M. Wasserman is an academic researcher from Amgen. The author has contributed to research in topics: Evolocumab & PCSK9. The author has an hindex of 49, co-authored 126 publications receiving 14981 citations. Previous affiliations of Scott M. Wasserman include Center for Global Development & University of Cape Town.
Papers
More filters
Journal ArticleDOI
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine,Robert P. Giugliano,Anthony C Keech,Narimon Honarpour,Stephen D. Wiviott,Sabina A. Murphy,Sabina A. Murphy,Julia F Kuder,Julia F Kuder,Huei Wang,Thomas Liu,Scott M. Wasserman,Peter S. Sever,Terje R. Pedersen,Terje R. Pedersen +14 more
TL;DR: In this trial, inhibition of PCSK9 with evolocumab on a background of statin therapy lowered LDL cholesterol levels to a median of 30 mg per deciliter (0.78 mmol per liter) and reduced the risk of cardiovascular events.
Journal ArticleDOI
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
Michael R. McClung,Andreas Grauer,Steven Boonen,Michael A. Bolognese,Jacques P. Brown,Adolfo Diez-Perez,Bente L. Langdahl,Jean-Yves Reginster,Jose R. Zanchetta,Scott M. Wasserman,Leonid Katz,Judy Maddox,Y.-C. Yang,Cesar Libanati,Henry G. Bone +14 more
TL;DR: In postmenopausal women with low bone mass, romosozumab was associated with increased bone mineral density and bone formation and with decreased bone resorption.
Journal ArticleDOI
Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial
Stephen J. Nicholls,Stephen J. Nicholls,Rishi Puri,Todd J. Anderson,Christie M. Ballantyne,Leslie Cho,John J.P. Kastelein,Wolfgang Koenig,Wolfgang Koenig,Ransi Somaratne,Helina Kassahun,Jingyuan Yang,Scott M. Wasserman,Rob Scott,Imre Ungi,Jakub Podolec,Antonius Oude Ophuis,Jan H. Cornel,Marilyn Borgman,Danielle M. Brennan,Steven E. Nissen +20 more
TL;DR: Among patients with angiographic coronary disease treated with statins, addition of evolocumab, compared with placebo, resulted in a greater decrease in PAV after 76 weeks of treatment, and further studies are needed to assess the effects of PCSK9 inhibition on clinical outcomes.
Journal ArticleDOI
Inhibition of PCSK9 With Evolocumab in Homozygous Familial Hypercholesterolaemia (TESLA Part B): A Randomised, Double-Blind, Placebo-Controlled Trial
Frederick J. Raal,Narimon Honarpour,Dirk J. Blom,G. Kees Hovingh,Feng Xu,Rob Scott,Scott M. Wasserman,Evan A. Stein +7 more
TL;DR: In patients with homozygous familial hypercholesterolaemia receiving stable background lipid-lowering treatment and not on apheresis, evolocumab 420 mg administered every 4 weeks was well tolerated and significantly reduced LDL cholesterol compared with placebo.
Journal ArticleDOI
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2) : a randomised, double-blind, placebo-controlled trial
Frederick J. Raal,Evan A. Stein,Robert Dufour,Traci Turner,Fernando Civeira,Lesley J. Burgess,Gisle Langslet,Russell S. Scott,Anders G. Olsson,David R. Sullivan,G. Kees Hovingh,Bertrand Cariou,Ioanna Gouni-Berthold,Ransi Somaratne,Ian Bridges,Rob Scott,Scott M. Wasserman,Daniel Gaudet +17 more
TL;DR: In patients with heterozygous familial hypercholesterolaemia, evolocumab administered either 140 mg every 2 weeks or 420 mg monthly was well tolerated and yielded similar and rapid 60% reductions in LDL cholesterol compared with placebo.